Drug News

UniQure to Implement 20% Workforce Reduction in Major Restructuring Move

Dutch gene therapy company uniQure N.V. has announced a significant restructuring plan aimed at cost-saving measures. As part of this strategic overhaul, the company plans to reduce its total workforce by approximately 20% and discontinue investments in over half of its ongoing research and technology projects. This decision reflects UniQure’s commitment to streamline its operations and focus on core initiatives that align with its long-term goals.

The primary objective of this restructuring is to improve efficiency and financial sustainability. By reducing its workforce and discontinuing certain research and technology projects, UniQure seeks to allocate its resources more effectively, ultimately ensuring that it can remain a leading player in the gene therapy field.

It’s worth noting that while this restructuring will bring about notable changes within the organization, it will not impact the manufacturing of the multi-million-dollar gene therapy product known as Hemgenix for CSL Behring. This demonstrates the company’s dedication to honoring its existing commitments and partnerships, particularly those that contribute significantly to its revenue and overall business success.

Hemgenix, developed by UniQure, is a gene therapy product with potentially life-changing applications. CSL Behring, a global biotech leader, has partnered with UniQure to bring this therapy to the market, with a focus on addressing unmet medical needs. The decision to maintain the manufacturing of Hemgenix underscores the importance of delivering critical therapies to patients while optimizing internal operations for sustainability.

UniQure’s announcement of a workforce reduction and the discontinuation of certain research projects is part of a strategic move to strengthen the company’s financial position and focus on core initiatives. By ensuring the manufacturing of Hemgenix for CSL Behring remains unaffected, UniQure aims to maintain its commitments and continue making a positive impact in the field of gene therapy, providing innovative solutions to patients in need.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker